Influx Healthtech share price
NSE: INFLUXPharmaceuticals & Biotechnology
Influx Healthtech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2025 · Issue price ₹96
Last close ₹270.05up ₹16.20 (6.38%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹253.85.
28 Oct: open ₹259.95, high ₹274.95, low ₹259.05
52-week range of traded prices to 28 Oct 2026
₹169.00Low, 30 Oct 2025₹315.00High, 6 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹625 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 30.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 6.20
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 20.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 25,20095.2% delivered
Results
Consolidated; ₹ crore.Influx Healthtech half-yearly results
Year to Mar 2026
- Revenue
- ₹147 Cr
- Net profit
- ₹21 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 14.0%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 147 |
| Net profit | 21 |
| Net margin | 14.0% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Half year to Mar 2026
- Revenue
- ₹147 Cr
- Net profit
- ₹21 Cr
- Net margin
- 14.0%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 147 |
| Net profit | 21 |
| Net margin | 14.0% |
Consolidated. The half year to Mar 2026, the first on record. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical and Healthcare industry, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Influx Healthtech PE ratio and valuation
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 60% of 237 trading days since Nov 2025.
LowestHighest
Its median5.92Industry median2.94
Influx Healthtech competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Influx Healthtech in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Aptus PharmaAPPL | 794 | 99.82 | 27.92 | – | – | 31.7% | – | 0.00% |
 Zim LaboratoriesZIMLAB | 758 | 205.08 | 2.56 | +7.6% | −60.6% | 1.3% | 1.8% | 0.00% |
 Kilitch Drugs (India)KILITCH | 752 | 25.01 | 2.69 | +14.0% | – | 12.5% | 8.9% | 0.00% |
 Valiant LaboratoriesVALIANTLAB | 683 | 42.70 | 2.20 | +89.6% | +12,324.8% | 5.9% | 7.0% | 0.00% |
 Amanta HealthcareAMANTA | 623 | 42.42 | 2.83 | – | – | 6.7% | 9.0% | 0.00% |
 WanburyWANBURY | 609 | 10.90 | 4.22 | +3.6% | +30.0% | 54.9% | 23.3% | 0.00% |
 Trident LifelineTLL | 516 | 22.79 | 4.54 | – | – | 24.0% | – | 0.00% |
 KRM AyurvedaKRMAYURVED | 507 | – | 4.42 | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Influx Healthtech announcements
Oct 2026
28 Oct · Board meeting
Sep 2026
24 Sep · General Updates
23 Sep · Analysts
18 Sep · Meeting
Influx Healthtech share price by year
Each calendar year to 2025.Influx Healthtech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 226.10 | – | 242.05 | 124.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 25 Jun 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 260.00 | 264.45 | 250.00 | 253.85 | 257.48 | 29,400 | 83.7% |
| 26 Oct 2026 | 259.00 | 261.00 | 251.25 | 257.25 | 258.00 | 10,200 | 82.4% |
| 23 Oct 2026 | 260.80 | 264.90 | 256.00 | 257.00 | 260.03 | 30,000 | 80.0% |
| 22 Oct 2026 | 255.00 | 258.10 | 255.00 | 258.10 | 257.27 | 2,400 | 100.0% |
| 21 Oct 2026 | 256.00 | 272.00 | 245.30 | 262.65 | 258.69 | 53,400 | 71.9% |
| 19 Oct 2026 | 260.00 | 262.95 | 253.60 | 259.50 | 258.98 | 10,200 | 82.4% |
| 16 Oct 2026 | 270.25 | 272.05 | 255.00 | 262.75 | 265.00 | 40,200 | 67.2% |
| 15 Oct 2026 | 270.00 | 275.95 | 266.00 | 272.90 | 270.07 | 15,600 | 69.2% |
| 14 Oct 2026 | 265.00 | 277.00 | 265.00 | 273.00 | 271.55 | 26,400 | 75.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- INFLUX
- ISIN
- INE0MYZ01012
- Industry
- Pharmaceuticals & Biotechnology